Genetically Modified Cells TRIZ Cases

Autologous p50-deficient immature myeloid cells overcome poor tumor localization of mature macrophages to enhance anti-tumor T cell immunity.

Sorting CD90-positive human urine-derived cells resolves heterogeneity to boost myotube induction efficiency.

Monoclonal antibody targets CSE epitopes to resolve cross-reactivity with other sulfated polysaccharides.

A TIL expansion method uses autologous peripheral blood lymphocytes as feeder cells to support therapeutic cell growth in closed systems.

Direct insertion of amplified nucleic acids into expression vectors bypasses intermediate cloning steps, reducing isolation time.

Engineered CHO cells express hsa-miR-431 mimics to suppress negative regulatory host genes and increase antibody concentration.

Genetic engineering eliminates retrotransposons to address age-associated disease burdens while maintaining genome integrity.

Late-outgrowth endothelial progenitor cells enable efficient nuclear reprogramming into induced pluripotent stem cells.

A droplet microfluidics system encapsulates isolated mitochondria and recipient cells to enable precise mitochondrial transfer.

Engineering endothelial cells with specific transcription factors creates a supportive microenvironment for hematopoietic stem cell culture.

Inactivating complement inhibitor genes in donor cells removes serum interference, enabling detection of low-level antibodies that traditional methods miss.

Recombinant autocrine motility factor stimulates mesenchymal stromal cell migration and adhesion via AMFR receptor activation.

Adjusting DMSO concentrations in CHO cell culture resolves variable glycosylation profiles, ensuring consistent high mannose and low fucosylated glycan levels.

Reducing enolase activity redirects metabolic flux, resolving the contradiction between high productivity and pathway stability.

Minicircle DNA vectors deliver reprogramming factors to adipose stem cells, avoiding genomic integration risks while maintaining high efficiency.